Dow Jones 13627.64 -5.44 4:47 am PDT, June 1, 2007 NASDAQ 2604.52 +0.00 For info, visit access.smallcapnetwork.com S & P 500 1530.62 +0.00 Change your subscription status here Russell 2000 847.18 +0.00 VOLUME 07 : ISSUE 54 MIVT: The End of the Beginning  As hard as some of us might try to make investing a complicated matter, sometimes I really think the wise investment move is just to take things at face value. That's what I thought of when I read last night's news from MIV Therapeutics (OTCBB: MIVT) anyway....the news is what it is. No angles, no fine print - just a milestone I'm sure many of you have been waiting for. And yes, I think this may be the catalyst the stock needs, now that an idea has become reality.  Normally I'd throw out a little teaser here and hope to build some suspense, but I'm not feeling like Michael Creighton today - this is too important. As of yesterday, one of MIV's next-generation heart stents has been implanted into a human patient in Brazil. Thus, the clinical trial phase of the coated stent's evolution has begun. If the trials proceed as well as the pre-clinical research suggests they will, I personally believe the win for the medical community could be the only victory bigger than the win for the company's stock. I'm guessing for some of you who've been following the MIV story, I could wrap things up right there - the research and work so far has now basically gotten past the 'end of the beginning' stage. I'd consider clinical trials more like the beginning of the middle.  If instead you're not familiar with what the big deal is about MIV's heart stents, then I strongly recommend you keep reading. The biotechnology is as impressive as the growth opportunity for the company's stock.    Putting The 'Tech' Back Into Biotechnology  I'm not a doctor....I don't even play one on TV. That's a good thing for all of us though, since it forces me to understand this stuff in plain English, which in turn allows me to explain it in plain English. A stent is just a mesh wire tube that acts as a scaffold for a blocked artery. When they were introduced in 1993, they were hailed as a breakthrough. The tune has changed for the worse a couple of times since then. Why? As it turns out, the stents may be doing more harm than good. Early metal stents as an experiment were fine, but as a standard treatment for actual patients, putting raw metal into a bloodstream is not ideal. There's the possibility a stent could break, and leave metal fragments in the bloodstream (near the heart, no less), or there was the high possibility of an infection where the metal was pressed up against artery walls...and those were just the obvious potential complications.  To avoid those kinds of problems, medical manufacturers began making stents with specialized medical coatings. From some perspectives, they worked - no longer would a heart patient have to worry about the dangers of foreign metal objects in their body. The downside is, they created a whole new set of problems. These coatings have now been linked to blood clotting, and scarring (thrombosis) near the affected area. In some cases, the coated stents are even blamed for fatal heart attacks...the very thing they were designed to prevent. So it's a trade-off only affecting the medical community? Not quite - this has had repercussions for a huge number of investors as well. As evidence of just how big the problem is......Johnson & Johnson (NYSE: JNJ) recently announced they were discontinuing the pre-clinical development of a coating, not to mention they were discontinuing sales of the underlying stent. And, you may recall late last year that Boston Scientific's (NYSE: BSX) coated 'Taxus' stent as well as JNJ's coated 'Cypher' stent have led to enormous class action lawsuits, ultimately costing the shareholder's of those companies.  Enter MIV Therapeutics. They've been working on a coated stent that (1) works, and (2) doesn't cause even more harm. Their own internal testing shows they've done exactly that, but the viability of their stent has also been validated by other parties performing longevity tests.  How'd they do it? In a nutshell, the coating they use is the same stuff teeth and bones are made of. Simple yet brilliant. Fortunately they own the patent on the coating, which allows them to protect their shareholder's profits on the technology for many years.  And now, they just took a giant step towards the commercialization of the stent. It all starts with one patient; I doubt the next one is too far off. Pretty soon, I suspect the company will have a full-blown clinical trial on their hands, which I firmly believe will get a buzz started within the investment community.    Some Bang For Your Biotech Buck  I have to be blunt here (as if I'm usually not).....I'm stunned you can still own this stock at 60 cents. My only guess is the rest of the market doesn't fully understand the kind of potential numbers we're seeing here. I don't particularly have a problem with the story not being viral yet, as in my experience, great investment stories eventually get told. My concern is in how it gets told. If a fund manager wakes up one day and likes the idea, they could easily take on a huge piece of the 80 million or so outstanding shares and send the stock rocketing higher at the drop of the hat, leaving any procrastinators behind the eight ball.  Or - and I have no specific reason to expect it - I have to wonder if MIV is a potential acquisition target. It's just chatter, but considering the company's entire market cap is only $48 million, it wouldn't take much for a JNJ or a Boston Scientific to buy their way back into the thick of the $7 billion stent market by using a successful and proven stent coating. Just a thought.  In the meantime, here's the rough math we did a couple of months ago - let's say a successfully-approved MIV heart stent can capture just 5% of that potential $7 billion market (conservative, in our opinion). That would mean annual sales of about $350 million to be spread out over just 80 million I&O shares, or per-share revenue of about $4.37. Yet, the current trading level is only 60 cents per share?!?! With most price/sales ratios somewhere around 3.0, based on our hypothetical market penetration you could actually justify a valuation of at least $10.00, if not more. I'd be the first to say the risk compared to the potential reward seems hard to believe. The risk is just that MIV's coating doesn't work out, and the stock goes nowhere. The reward? MIV's coating does work out, and this $48 million company could eventually be doing hundreds of millions in stent sales each year. As an investor, I think the potential upside dwarfs any downside, which is the name of the game for me - a positive risk/reward scenario.  Like I first said, sometimes the wise investment move is just taking things at face value, and I think this is one of those times. Their first stent is now in a human patient; more will follow. Other competitors in this lucrative heart stent market are back-pedaling, or getting out altogether....the liability is just too great for them with their current product line. MIV Therapeutics, on the other hand, is picking up steam.  Bottom line - I believe today's MIVT owners could be very well rewarded for taking the time to understand just how big their potential upside is. Our suggested target of $1.65 still stands.    MIV Therapeutics Announces Start of Clinical Trial Marking First Ever Human Implantation of a Hydroxyapatite Coated Stent  Trial to Study Safety and Efficacy of One of the Company's Proprietary Polymer-Free Drug-Eluting Stent Technologies  ATLANTA-- MIV Therapeutics (OTCBB:MIVT)(FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, today announced the first ever human implantation of a hydroxyapatite coated stent and the launch of the MIVT Pilot Trial.  The MIVT Pilot Trial will evaluate the safety and efficacy of MIVT's polymer-free nanoscale microporous hydroxyapatite drug-eluting stent for the treatment of single de novo lesions in native coronary arteries.  The first procedure was conducted by Dr. Alexandre Abizaid of Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil. Dr. Abizaid and Institute Dante Pazzanese of Cardiology are among the world's foremost experts in conducting clinical trials researching both new and existing drug-eluting stents.  The beginning of human implantation represents the culmination of extensive research and development and a successful animal trial program. Human implantation represents a crucial milestone in MIVT's strategic plan to develop a new class of polymer-free drug-eluting stents that could provide patients with superior outcomes. "We are very pleased to announce that our human trials are underway in-line with our previous guidance," said Dr. Mark Landy, President of MIV Therapeutics. "We have worked diligently to create a new, novel technology that we expect will be an excellent alternative for millions of patients around the world suffering from coronary artery disease.  MIV Therapeutics is focused on commercializing the next generation of fully biocompatible coatings for cardiovascular stents and drug delivery systems to treat coronary artery disease, an estimated $6 billion worldwide market. The company's technologies are expected to offer a safer alternative to current drug-eluting stents and hope to solve the issues of late thrombosis.  MIVT's polymer-free nanoscale microporous hydroxyapatite drug-eluting stent uses the Company's GenX coronary stent system. The GenX stent is coated with one of MIVT's proprietary hydroxyapatite polymer-free drug eluting systems that is 700 nanometers thin.  About MIV Therapeutics Inc.  MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. MIVT's intellectual property portfolio includes patents held by the University of British Columbia (UBC). MIVT has worldwide exclusive rights to the technologies licensed from UBC. Key patent applications filed simultaneously in various countries around the world, further protect the commercial exclusivity of MIVT's own inventions in the global marketplace. For more information please visit www.MIVTherapeutics.com.  For investor information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.  Forward-Looking Statements  Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "proposed," "expected," "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties including, without limitation, the potential for the unsuccessful closing by the Company of its Vascore acquisition, together with the raising of funding sufficient to continue with its operations and those contemplated by the Company as a consequence thereof, and the ability of the Company to raise sufficient funding and to continue to develop its various business interests as presently contemplated. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.  Contacts  MIV Therapeutics Inc.  Investor Relations, 604-301-9545, x14  Toll-free: 800-221-5108  Fax: 604-301-9546  investor@mivtherapeutics.com  http://www.mivtherapeutics.com/ or  Trilogy Capital Partners  Financial Communications  Ryon Harms, Toll-free: 800-592-6067  ryon@trilogy-capital.com    We Value Your Feedback   Got comments, questions or suggestions? Send 'em on over: Email the Editor If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 4653 Carmel Mtn Rd Suite 308 #402 San Diego, CA 92130 Subscribe Information is power and timely information is profitable. Become informed and profit from Small Cap Network Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the Small Cap Network Email Newsletter on a regular basis. To ensure newsletter delivery, you can add any additional email addresses you may have to the Small Cap Network Member List. Receiving the Small Cap Network Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the Small Cap Network recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery. Subscribe Here Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the Small Cap Network Newsletter, simply follow the instructions located at the bottom of every Small Cap Network Newsletter Edition. Unsubscribe Here D I S C L A I M E R: The Small Cap Network, its website and email newsletter (hereafter, cumulatively referred to as "SCN") , is an independent electronic publication committed to providing its readers with factual information on select publicly traded companies. SCN is owned and operated by TGR Group, LLC ("TGR"). All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. Moreover, as detailed below, TGR accepts compensation from third party consultants and/or companies, which it features in the publication and circulation of SCN. To the degrees enumerated herein, SCN should not be regarded as an independent publication.  Click Here or go to http://access.smallcapnetwork.com/compensation_disclosure.html to view our compensation on every company we have ever covered, or visit the following web address: http://access.smallcapnetwork.com/profile_disclosure.html for our full profiles and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts.  From March of 2005 through July of 2006, TGR Group LLC was paid a fee of $40,000 by MIV Therapeutics for coverage of the company. In addition, TGR Group LLC was also awarded 272,000 warrants with an exercise price of $.26 by Trilogy Capital Partners for coverage of MIV Therapeutics. All of the aforementioned warrants have been exercised and shares have been sold in the open market. On April 3rd of 2007, MIV Therapeutics renewed coverage and paid TGR Group, LLC $30,000 in cash and 100,000 warrants, convertible into restricted shares at $.50. In addition, TGR Group has been awarded 190,000 warrants, convertible at $.50 into free trading shares, by Trilogy Capital Partners for coverage of the company. From time to time TGR sells shares received as compensation for coverage of client companies. Shares received are sold in the open market. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, TGR does not view the sale of the shares as contradictory to any opinions delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.  TGR, its Members and Members' families, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed.  All statements and expressions are the sole opinions of TGR and are subject to change without notice. A profile, description, or other mention of a company within SCN is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.  The profiles, critiques, and other editorial content of SCN may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.  THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF TGR.  We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.